Fulltext

Pre-diagnostic circulating insulin-like growth factor-I and bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition

Lin C 1 , Travis RC 1 , Appleby PN 1 , Tipper S 1 , Weiderpass E 2 , Chang-Claude J 3 Show all authors , Gram IT 4 , Kaaks R 3 , Kiemeney LA 5 , Ljungberg B 6 , Tumino R 7 , Tjønneland A 8 , Roswall N 8 , Overvad K 9 , Boutron-Ruault MC 10 , Manciniveri FR 10 , Severi G 10 , Trichopoulou A 11 , Masala G 12 , Sacerdote C 13 , Agnoli C 14 , Panico S 15 , Bueno-de-Mesquita B 16 , Peeters PH 17 , Salamanca-Fernández E 18 , Chirlaque MD 19 , Ardanaz E 19 , Dorronsoro M 20 , Menéndez V 21 , Luján-Barroso L 22 , Liedberg F 23 , Freisling H 24 , Gunter M 24 , Aune D 25 , Cross AJ 25 , Riboli E 25 , Key TJ 1 , Perez-Cornago A 1

Affiliations 

  • 1 Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
  • 2 Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway
  • 3 German Cancer Research Center (DKFZ), Heidelberg, Germany
  • 4 Faculty of Health Sciences, Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway
  • 5 Radboud University Medical Center, Department for Health Evidence and Department of Urology, Nijmegen, The Netherlands
  • 6 Department of Surgical and Perioperative sciences, Urology and Andrology, Umeå University, Umeå, Sweden
  • 7 Cancer Registry and Histopathology Department, "Civic - M. P. Arezzo" Hospital, Ragusa, Italy
  • 8 Danish Cancer Society Research Center, Copenhagen Ø, Denmark
  • 9 Aarhus University, Department of Public Health Section for Epidemiology, Aarhus, Denmark
  • 10 CESP, Faculté de Médecine, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
  • 11 Hellenic Health Foundation, Athens, Greece
  • 12 Cancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute, ISPO, Florence, Italy
  • 13 Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy
  • 14 Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  • 15 Dipartimento di Medicine Clinica e Chirurgia, Federico II University, Naples, Italy
  • 16 Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
  • 17 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
  • 18 Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs, GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
  • 19 CIBER Epidemiology and Public Health CIBERESP, Madrid, Spain
  • 20 Public Health Direction and Biodonostia Research Institute-Ciebersp, Basque Regional Health Department, Vitoria-Gasteiz, Spain
  • 21 Public Health Directorate, Asturias, Spain
  • 22 Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
  • 23 Department of Translational Medicine, Lund University and Department of Urology, Skåne University Hospital, Malmö, Sweden
  • 24 Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France
  • 25 Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom
Int J Cancer, 2018 Nov 15;143(10):2351-2358.
PMID: 29971779 DOI: 10.1002/ijc.31650

Abstract

Previous in vitro and case-control studies have found an association between the insulin-like growth factor (IGF)-axis and bladder cancer risk. Circulating concentrations of IGF-I have also been found to be associated with an increased risk of several cancer types; however, the relationship between pre-diagnostic circulating IGF-I concentrations and bladder cancer has never been studied prospectively. We investigated the association of pre-diagnostic plasma concentrations of IGF-I with risk of overall bladder cancer and urothelial cell carcinoma (UCC) in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 843 men and women diagnosed with bladder cancer between 1992 and 2005 were matched with 843 controls by recruitment centre, sex, age at recruitment, date of blood collection, duration of follow-up, time of day and fasting status at blood collection using an incidence density sampling protocol. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression with adjustment for smoking status. No association was found between pre-diagnostic circulating IGF-I concentration and overall bladder cancer risk (adjusted OR for highest versus lowest fourth: 0.91, 95% CI: 0.66-1.24, ptrend = 0.40) or UCC (n of cases = 776; 0.91, 0.65-1.26, ptrend = 0.40). There was no significant evidence of heterogeneity in the association of IGF-I with bladder cancer risk by tumour aggressiveness, sex, smoking status, or by time between blood collection and diagnosis (pheterogeneity > 0.05 for all). This first prospective study indicates no evidence of an association between plasma IGF-I concentrations and bladder cancer risk.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications